论文部分内容阅读
瑞美隆(Remeron)的国际通用名是米他扎品(Mirtazapine).其药理机制与以往的各类抗抑郁药不同,被称为Nassa(Noradrenergic and Specific Serotonergic Antidepressants,去甲肾上腺素和特异的五羟色胺抗抑郁药)。本文就该药的药理特性、临床疗效及不良反应作一概述。 1 药理特性 1.1 作用机制 瑞美隆的作用机制与以前我们所知的任何一种抗抑郁药均不相同,它同时作用于去甲肾上腺素神经和5-HT神经,促使去甲肾上腺素(NA)和5-HT的神经传导,起抗抑郁作用。神经生理学研究表明,瑞美隆通过三种途径起抗抑郁作用:(1)作用于脑去甲肾上腺素突触前膜α_1自身受体,增加去甲肾上腺素神经冲动发放,促使NA释放,起部分抗抑郁作用。(2)5-HT神经冲动发放受5-HT神经细胞上的
Remeron’s international common name is Mirtazapine, a pharmacological mechanism unlike previous antidepressants known as Nassa (Noradrenergic and Specific Serotonergic Antidepressants, Norepinephrine and Specific Serotonin antidepressants). This article on the pharmacological properties of the drug, clinical efficacy and adverse reactions are summarized. 1 pharmacological properties 1.1 Mechanism of action Remeron’s mechanism of action and previously we know of any kind of antidepressants are not the same, it acts on both norepinephrine and 5-HT nerve, to promote norepinephrine (NA ) And 5-HT nerve conduction, antidepressant effect. Neuropsychological studies have shown that Simmeron acts as an anti-depressant in three ways: (1) acting on the neuronal presynaptic alpha-1 receptor of the brain, increasing the release of norepinephrine nerve impulses and promoting the release of NA Partial antidepressant effect. (2) 5-HT nerve impulses are released on 5-HT neurons